ACM
Aisling Capital Management Portfolio holdings
AUM
$360M
1-Year Est. Return
114.67%
1 Year Est. Return
+114.67%
AUM
$360M
AUM Growth
+$71.2M
(+25%)
Holding
13
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$10.5B
| $262M | 72.85% |
6,068,125
|
|
||
|
VRNA
2
DELISTED
Verona Pharma
VRNA
| $58.2M | 16.18% |
615,352
|
|
||
3
Syndax Pharmaceuticals
SNDX
$1.3B
| $12.3M | 3.43% |
1,316,806
+291,806
|
|
||
4
Monte Rosa Therapeutics
GLUE
$637M
| $6.64M | 1.85% |
1,472,331
|
|
||
|
BCAX
5
Bicara Therapeutics
BCAX
$1.02B
| $5.29M | 1.47% |
568,919
|
|
||
6
Nuvation Bio
NUVB
$1.24B
| $4.95M | 1.38% |
2,541,009
|
|
||
7
Biomea Fusion
BMEA
$112M
| $3.69M | 1.03% |
2,048,757
+1,250,000
|
|
||
|
CMPS
8
Compass Pathways
CMPS
$615M
| $3.36M | 0.93% |
1,198,418
|
|
||
|
ELEV
9
DELISTED
Elevation Oncology
ELEV
| $1.04M | 0.29% |
2,834,910
|
|
||
10
CalciMedica
CALC
$45.4M
| $834K | 0.23% |
521,114
|
|
||
11
Aclaris Therapeutics
ACRS
$222M
| $617K | 0.17% |
434,455
|
|
||
12
Marker Therapeutics
MRKR
$13.3M
| $498K | 0.14% |
325,370
|
|
||
|
OKUR
13
OnKure Therapeutics
OKUR
$39M
| $212K | 0.06% |
88,607
|
|